Methotrexatedrug info
methotrexate 25 MG/ML Injectable Solution
What it is used for
Methotrexate Injection is a folate analog metabolic inhibitor indicated for:
The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen.
Treatment of adults with rheumatoid arthritis (RA).
Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
Treatment of adults with severe psoriasis.
1.1 Acute Lymphoblastic
Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen.
1.2 Meningeal
Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients.
1.3 Non-Hodgkin
Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma.
1.4 Osteosarcoma
Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen.
1.5 Breast Cancer
Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen.
1.6 Squamous
Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent.
1.7 Gestational
Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen.
1.8 Rheumatoid
Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA).
1.9 Polyarticular
Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA).
1.10 Psoriasis
Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective June 10, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
Methotrexate is a folate analog metabolic inhibitor with the chemical name of N -[4-[[(2,4-diamino-6-pteridinyl) methyl]methylamino]benzoyl]-L-glutamic acid and a molecular weight of 454.44. The molecular formula is C 20 H 22 N 8 O 5, and the structural formula is shown below: Methotrexate Injection with preservative is supplied in sterile multiple-dose vials for intravenous, intramuscular, or subcutaneous use.
Each 25 mg/mL, 2 mL vial contains 50 mg methotrexate equivalent to 54.8 mg of methotrexate sodium, 18.8 mg of benzyl alcohol as a preservative and Sodium chloride 5.2 mg. May contain sodium hydroxide and/or hydrochloric acid to adjust the pH to 8.5. Preservative-free Methotrexate Injection is supplied in sterile single-dose vials for intravenous, intramuscular, subcutaneous, or intrathecal use.
Each 25 mg/mL, 40 mL vial contains 1000 mg methotrexate equivalent to 1096.7 mg of methotrexate sodium, and the following inactive ingredients: Sodium chloride 196 mg. May contain sodium hydroxide and/or hydrochloric acid to adjust pH to 8.5. Chemical Structure
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective June 10, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance